On April 2 2009, the FDA had an Advisory Committee meeting to discuss Novo-Nordisk's application to sell their new diabetes drug, liraglutide. The FDA routinely turns to Advisory Committees for input about the safety and/or efficacy of drugs they are reviewing, but then the FDA makes the final deci...
-
sulfonylurea mimetics?
frankenduf
Tuesday, April 14, 2009 at 03:30 PM -
Availability, if ever
Miranda Kelly
Friday, April 17, 2009 at 01:48 AMWhen do you think they'd release this drug? And do you think they sell liraglutide in online prescription medication stores?
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
nice post- this clearly is a 'me-too' drug, but to me the irony is in the other qualification: does it work?- compared to insulin, followed by metformin and the SUs, the relative capacity to lower A1Cs for the synthetic incretins is low indeed- where is the cost benefit line of comparing new drug X with old treatments, which are proven more effective, cheaper, and safer (with many more years of patient administration under their belt)- in my opinion, the insulin mimetics clearly are NOT revolutionary new treatments, in terms of effects, and as such should be very carefully scrutinized before being released to the guinea pigs, i mean public.